Skip to main content

Table 2 Assessment scales of the study population

From: The effect of concomitant fibromyalgia in HIV infected patients receiving antiretroviral therapy: a prospective cross-sectional study

Assessment scales

Total of patients

n = 225 (%)

With FMS

n = 45 (%20)

Without FMS

n = 180 (%80)

p* values

FIQ

35.68 ± 22.72

58.53 ± 19.58

29.97 ± 19.69

0.001

BDI

16.41 ± 12.63

26.33 ± 14.51

13.93 ± 10.81

0.001

PSQI

6.16 ± 3.94

8.67 ± 3.87

5.53 ± 3.71

0.001

FSS

4.09 ± 1.82

5.49 ± 1.14

3.75 ± 1.79

0.001

SF-36

 Physical function (PF)

80.33 ± 27.68

52.00 ± 34.48

87.42 ± 20.36

0.001

 Physical role (PR)

64.67 ± 39.27

36.67 ± 39.02

71.67 ± 36.17

0.001

 Emotional role (ER)

58.67 ± 40.77

22.22 ± 31.78

67.77 ± 37.61

0.001

 Vitality (V)

56.53 ± 25.00

32.67 ± 19.96

62.50 ± 22.47

0.001

 Mental health (MH)

56.53 ± 22.81

44.27 ± 16.87

59.60 ± 23.11

0.001

 Social function (SF)

69.37 ± 26.47

50.83 ± 27.49

74.00 ± 24.14

0.001

 Bodily pain (BP)

70.03 ± 24.17

49.50 ± 27.84

75.17 ± 20.20

0.001

 General health (GH)

55.07 ± 25.69

33.00 ± 23.34

60.58 ± 23.21

0.001

  1. FIQ Fibromyalgia Impact Questionnaire, BDI Beck Depression Inventory, PSQI Pittsburgh Sleep Quality Index, FSS Fatigue Severity Scale, SF-36 Short- Form 36
  2. * p < 0.05 was considered significant